University Health Network
🇨🇦Canada
Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah
Phase 1
Withdrawn
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT06003179
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
At-home Breast Oncology Care Delivered With E-health Solutions
Not Applicable
Recruiting
- Conditions
- Patient EngagementPatient Reported Outcome MeasuresPatient Activation
- Interventions
- Other: At-home Breast Oncology care Delivered with E-health solutions - ABODE
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 200
- Registration Number
- NCT05989477
- Locations
- 🇨🇦
Tulin Cil, Toronto, Ontario, Canada
Impact of Cultural and Linguistic Backgrounds on Patient Care and Experience of Women With Gynecologic Malignancies
Active, not recruiting
- Conditions
- Gynecologic Cancer
- Interventions
- Other: Questionnaire
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 45
- Registration Number
- NCT05971303
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Investigating LFP Correlates of TUS in Patients With Movement Disorders
Not Applicable
Recruiting
- Conditions
- Parkinson DiseaseEssential TremorDystonia
- Interventions
- Device: TUS ShamDevice: TUS Active
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 25
- Registration Number
- NCT05965960
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 19
- Registration Number
- NCT05963217
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study
Not Applicable
Not yet recruiting
- Conditions
- High Grade Serous Ovarian Cancer (HGSOC)
- Interventions
- Radiation: FAPI PET CT
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT05956093
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
Phase 1
Recruiting
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- Radiation: TLI
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT05950802
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
IVIM & OLINK in Sarcoma
Phase 2
Recruiting
- Conditions
- Soft Tissue Sarcoma
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 145
- Registration Number
- NCT05950594
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
A Novel Combined Neuromodulation Therapy to Enhance Balance and Neuroplasticity
Not Applicable
Not yet recruiting
- Conditions
- Muscle ParesesFallSpinal Cord Injuries
- Interventions
- Other: Activity-based rehabilitation+electrical stimulation
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT05940636
- Locations
- 🇨🇦
Toronto Rehabilitation Institute-Lyndhurst Center, Toronto, Ontario, Canada
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Phase 2
Recruiting
- Conditions
- Kidney Transplant Recipients
- Interventions
- Drug: Semaglutide, 1.0 mg/mL
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT05938712
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath